Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2880070 + Gemcitabine in Ewing Sarcoma
NCT05275426Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LY2880070 in Ewing sarcoma, Ewing-like sarcoma and desmoplastic small round cell tumor (DSRCT), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Best Overall Response Rate at 6 months. Started Mar 2022; status: completed.
02
Drugs
LY2880070
03
Conditions
Ewing sarcomaEwing-like sarcomadesmoplastic small round cell tumor (DSRCT)
Beyond the preview
Go deeper on NCT05275426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275426.